Abnormalities of uterine cervix in women with inflammatory bowel disease

Table 1 Patient demographics: IBD vs controls

Patient demographics	Total IBDn = 116	Controlsn = 116	P
Median age (yr) (range)	46.5 (17-74)	46 (19-72)
Ethnicity			0.025
Caucasian	93%	85%
Other (AA, Asian, Hispanic, Indian, Multicultural, West Indian)	7%	15%
Marital status			0.4
Single	21%	18%
Married	70%	64%
Divorced	7%	12%
Other (widow, unknown)	3%	6%
Abortions (n)			0.008
0	80%	65%
1	11%	17%
> 1	9%	18%
Disease severity1
Mild	56%
Moderate	31%
Severe	12%
Nonresponders	2%
Family history of IBD2
Yes	37%
No	61%
Unknown	3%
Disease duration in years
Median (yr) (range)	16 (1-55)
6MP use
n	55
Median (yr) (range)	6 (1-26)
Imuran use
n	9
Median (yr) (range)	3 (1-7)
Infliximab use
n	12
Median (yr) (range)	1 (1-2)

¹Combined patient-physician assessment;

²Includes at least one other first degree or second degree family member with IBD.

Table 2 Patient demographics: CD vs UC

Patient Demographics	CD64	UC52	P
Median age (yr) (range)	47 (20-72)	45 (17-74)	0.94
Ethnicity			0.666
Caucasian	59	49
Other (AA, Asian, Hispanic, Indian, Multicultural, West Indian)	5	3
Marital status			0.914
Single	14	10
Married	44	38
Divorced	4	3
Other (widow, unknown)
Abortions (n)			0.901
0	51	42
1	8	5
> 1	5	4
Disease severity1			0.2
Mild	31	33
Moderate	25	13
Severe	8	6
Family history of IBD2			0.14
Primary	18	10
Secondary	10	4
No family history	34	37
Disease duration in years
Median (yr) (range)	19 (1-55)	14 (1-40)	0.147
6MP use
n	39	16
Median (yr) (range)	6 (1-26)	6 (1-12)	0.628
Imuran use
n	6	3
Median (yr) (range)	4.5 (2-7)	3 (1-4)	0.433
Infliximab use
n	10	2
Median (yr) (range)	1 (1-2)	1 (1)	0.392

¹Combined patient-physician assessment;

²Includes at least one other first degree or second degree family member with IBD.

Table 3 PAP results in IBD patients vs controls

Pap results	IBD total	Controls	p
Normal	95	110
Abnormal	21	6
ASCUS1	11	2
LGSIL2	6	3
HGSIL3	4	1
Total	116	116
Abnormals (%)	18.1	5.2	0.004

¹Atypical Squamous Cells of Undetermined Significance;

²Low-grade squamous intraepithelial lesions;

³High-grade suamous intraepithelial lesions (including carcinoma in situ).

Table 4 PAP results in IBD subgroups: CD vs UC

Pap results	CD	UC	p
Normal	50	45
Abnormal	14	7
ASCUS1	7	4
LGSIL2	4	1
HGSIL3	3	2
Total	64	52
Abnormals (%)	22	13	0.793

¹Atypical Squamous Cells of Undetermined Significance;

²Low-grade squamous intraepithelial lesions;

³High-grade suamous intraepithelial lesions (including carcinoma in situ).

Table 5 HPV Data in IBD patients vs controls (for abnormal Pap results)¹

HPV status	IBD total	CD	UC	Controls
Positive (high risk)	5	5	0	2
Positive (low risk)	3	0	3	0
Negative	4	4	0	2
Unknown	9	5	4	2
Total	21	14	7	6

¹HPV data were available in a small subset of abnormal Pap results and in none of the normal Paps.

Table 6 Incidence of abnormal pap results in 116 IBD patients after treatment

Pap results	Normal papn (%)	Abnormal papn (%)	Total(n)	P
Corticosteroids	49 (80)	12 (20)	61	0.747
No corticosteroids	43 (83)	9 (17)	52
5-ASA1	88 (82)	20 (19)	108	0.934
No 5-ASA1	4 (80)	1 (20)	5
Immunosuppressives2 and Anti-TNF α3	54 (79)	14 (21)	68	0.381
No immunosuppressives2 and no Anti-TNF α3	42 (86)	7 (14)	49

¹5-aminosalicylates (sulfasalazine, mesalamine, olsalazine, etc);

²Monoclonal antibody to Tumor Necrosis Factor α (infliximab);

³6-mp and/or azathioprine.